AFACIFENACIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C27H26F3N3O2
Molecular Weight	481.5094
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

FC(F)(F)OC1=CC(CN2CCC(CC2)N3[C@@H](C4=CC=CC=C4)C5=C(NC3=O)C=CC=C5)=CC=C1

InChI

InChIKey=IJUMFEAYOMCXAQ-VWLOTQADSA-N

InChI=1S/C27H26F3N3O2/c28-27(29,30)35-22-10-6-7-19(17-22)18-32-15-13-21(14-16-32)33-25(20-8-2-1-3-9-20)23-11-4-5-12-24(23)31-26(33)34/h1-12,17,21,25H,13-16,18H2,(H,31,34)/t25-/m0/s1

HIDE SMILES / InChI

Description
Sources: https://adisinsight.springer.com/drugs/800022820

Afacifenacin is being developed by Sumitomo Dainippon Pharma (formerly Dainippon Sumitomo Pharma) and Sunovion Pharmaceuticals as an orally administered therapy for overactive bladder and nocturia. Afacifenacin is a new antimuscarinic that possesses the dual pharmacological actions of non-selective muscarinic receptor antagonist and inhibition of the bladder afferent pathway through sodium-channel blockade. Afacifenacin is in Phase II clinical tirals for the treatment of Nocturia by Nippon Shinyaku.

Originator

Approval Year

PubMed

Title	Date	PubMed
Phase II drugs that target cholinergic receptors for the treatment of overactive bladder.	2014 Oct	24899225

Sample Use Guides

In Vivo Use Guide

Overactive bladder: 20, 40, 80 and 120 mg/day, 8 weeks of treatment

Route of Administration: Oral

Name

Type

Language

AFACIFENACIN

Official Name

English

NS-986

Code

English

afacifenacin [INN]

Common Name

English

2(1H)-QUINAZOLINONE, 3,4-DIHYDRO-4-PHENYL-3-(1-((3-(TRIFLUOROMETHOXY)PHENYL)METHYL)-4-PIPERIDINYL)-, (4S)-

Systematic Name

English

(4S)-4-PHENYL-3-(1-((3-(TRIFLUOROMETHOXY)PHENYL)METHYL)PIPERIDIN-4-YL)-3,4-DIHYDROQUINAZOLIN-2(1H)-ONE

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29704